1. Home
  2. CDIO vs PMAX Comparison

CDIO vs PMAX Comparison

Compare CDIO & PMAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cardio Diagnostics Holdings Inc.

CDIO

Cardio Diagnostics Holdings Inc.

N/A

Current Price

$2.15

Market Cap

4.6M

Sector

Health Care

ML Signal

N/A

PMAX

Powell Max Limited

N/A

Current Price

$2.53

Market Cap

5.5M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
CDIO
PMAX
Founded
2017
2019
Country
United States
Hong Kong
Employees
17
53
Industry
Biotechnology: Commercial Physical & Biological Resarch
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6M
5.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CDIO
PMAX
Price
$2.15
$2.53
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
73.3K
2.4M
Earning Date
05-13-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$171,906.75
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.97
$0.20
52 Week High
$7.91
$5.20

Technical Indicators

Market Signals
Indicator
CDIO
PMAX
Relative Strength Index (RSI) 63.97 50.21
Support Level $1.68 $1.94
Resistance Level $2.35 $2.87
Average True Range (ATR) 0.17 0.45
MACD 0.08 -0.11
Stochastic Oscillator 96.28 29.05

Price Performance

Historical Comparison
CDIO
PMAX

About CDIO Cardio Diagnostics Holdings Inc.

Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.

About PMAX Powell Max Limited

Powell Max Ltd operates as a financial communications platform supporting listed companies and IPO applicants throughout the capital markets lifecycle. Substantially all of the company's revenue is generated from Hong Kong. The group focused on supporting the disclosure, reporting, and transaction needs of corporate clients and their advisors. Its mission is to combine industry knowledge, execution capabilities, and a commitment to service to deliver accurate, timely, and reliable solutions for customers.

Share on Social Networks: